← Back to patent-cliff list
[ 161 Tb]Tb PSMA I&T
Tier C — Watch / trade[ 161 Tb]Tb PSMA I&T
Peter Maccallum Cancer Centre, Australia
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：AR
Indications (approved)：Prostate cancer, Castration-resistant prostate cancer
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of [ 161 Tb]Tb PSMA I&T?
Approved indications include: Prostate cancer, Castration-resistant prostate cancer.
When does the [ 161 Tb]Tb PSMA I&T patent expire?
No public expiry year is available for [ 161 Tb]Tb PSMA I&T yet; this page updates once verified.
How do I get a quote for [ 161 Tb]Tb PSMA I&T intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05